🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in Germany / NCT06632301
Starting soon Not applicable

DEXA Bone Density Analysis of the CoreHip® Prosthesis System

NCT06632301 · tracked via the Priya Life Science Germany tracker
Phase
Not applicable
Started
2026-12
Last updated
2026-08-20

Condition(s) studied

Primary OsteoarthritisCartilage DegenerationOsteoarthritis, HipInflammatory ArthritisOsteonecrosis of Femoral HeadTraumatic Disorder

Investigational drug(s) / intervention(s)

Primary hip replacement with cementless stem

Primary hip replacement with cementless stem: Total Hip Arthroplasty is today one of the most established surgical orthopaedic procedures worldwide.

Study summary

The goal of this interventional post-market follow-up study is to evaluate radiological changes in the diaphyseal bone density (Gruen Zones 3 and 4) within 24 months postoperative in patients treated with CoreHip® primary cementless stem. The DEXA bone density analysis is used.

Eligibility

Sex
ALL
Min age
35 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: * Unilateral hip osteoarthritis * Indication for CoreHip Standard hip stem according to preoperative planning * Written Informed Consent * Age 35-85 years * According to the assessment of the study doctor, the patient is therapy compliant and able to attend the follow-up visits Exclusion Criteria: * Femoral neck fractures * Pregnancy * BMI \> 35 * History of femoral fracture or previous surgery on the same hip * Metabolic bone disease, use of steroids or other drugs affecting bone metabolism * Intraoperative bone cracks * Severe osteoarthritis of the contralateral hip * THA of the contralateral side or other event leading to restricted weight bearing during the study period

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Medizinische Hochschule Hannover Hanover Germany

More Aesculap AG trials in Germany

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06632301 on ClinicalTrials.gov ↗ ← All trials in Germany